| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Kinnate Biopharma Inc. | Director | Common Stock | 0 | $0 | $2.59 | 03 Apr 2024 | Direct |
| Clovis Oncology, Inc. | Director | Stock Option (right to buy) | 42,223 | 10 Jun 2021 | Direct | ||
| Checkmate Pharmaceuticals, Inc. | Director | Stock Option (Right to Buy) | 0 | 31 May 2022 | Direct | ||
| Kinnate Biopharma Inc. | Director | Stock Option (right to buy) | 0 | 03 Apr 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| KNTE | Kinnate Biopharma Inc. | 03 Apr 2024 | 7 | $0 | 4 | Director | 05 Apr 2024, 16:55 |
| KNTE | Kinnate Biopharma Inc. | 12 Jun 2023 | 1 | $0 | 4 | Director | 13 Jun 2023, 18:28 |
| KNTE | Kinnate Biopharma Inc. | 13 Jun 2022 | 1 | $0 | 4 | Director | 15 Jun 2022, 17:01 |
| CMPI | Checkmate Pharmaceuticals, Inc. | 31 May 2022 | 3 | $0 | 4 | Director | 31 May 2022, 10:12 |
| CMPI | Checkmate Pharmaceuticals, Inc. | 16 Jun 2021 | 1 | $0 | 4 | Director | 21 Jun 2021, 21:24 |
| KNTE | Kinnate Biopharma Inc. | 11 Jun 2021 | 1 | $0 | 4 | Director | 14 Jun 2021, 19:13 |
| CLVS | Clovis Oncology, Inc. | 10 Jun 2021 | 1 | $0 | 4 | Director | 11 Jun 2021, 21:02 |